- Home
- FCT vs ACIU Comparison
FCT vs ACIU Comparison
Compare FCT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCT
- ACIU
- Stock Information
- Founded
- FCT 2004
- ACIU 2003
- Country
- FCT United States
- ACIU Switzerland
- Employees
- FCT N/A
- ACIU N/A
- Industry
- FCT Finance Companies
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- FCT Finance
- ACIU Health Care
- Exchange
- FCT Nasdaq
- ACIU Nasdaq
- Market Cap
- FCT 261.0M
- ACIU 213.3M
- IPO Year
- FCT N/A
- ACIU 2016
- Fundamental
- Price
- FCT $10.07
- ACIU $2.13
- Analyst Decision
- FCT
- ACIU Strong Buy
- Analyst Count
- FCT 0
- ACIU 1
- Target Price
- FCT N/A
- ACIU $12.00
- AVG Volume (30 Days)
- FCT 106.8K
- ACIU 158.8K
- Earning Date
- FCT 01-01-0001
- ACIU 08-05-2025
- Dividend Yield
- FCT 11.29%
- ACIU N/A
- EPS Growth
- FCT N/A
- ACIU N/A
- EPS
- FCT N/A
- ACIU N/A
- Revenue
- FCT N/A
- ACIU $36,362,036.00
- Revenue This Year
- FCT N/A
- ACIU N/A
- Revenue Next Year
- FCT N/A
- ACIU $533.21
- P/E Ratio
- FCT N/A
- ACIU N/A
- Revenue Growth
- FCT N/A
- ACIU 86.71
- 52 Week Low
- FCT $9.45
- ACIU $1.43
- 52 Week High
- FCT $10.42
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- FCT 47.00
- ACIU 48.82
- Support Level
- FCT $9.99
- ACIU $2.05
- Resistance Level
- FCT $10.09
- ACIU $2.25
- Average True Range (ATR)
- FCT 0.08
- ACIU 0.17
- MACD
- FCT -0.02
- ACIU -0.02
- Stochastic Oscillator
- FCT 27.42
- ACIU 19.57
About FCT First Trust Senior Floating Rate Income Fund II of Beneficial Interest
First Trust Senior Floating Rate Income Fund II is a United States-based diversified, closed-end management investment company. Its investment objective is to seek a high level of current income. As a secondary objective, it attempts to preserve capital. The fund invests in a portfolio of senior secured floating-rate corporate loans (Senior Loans) of companies from different industries, such as Insurance, Software, Health Care Providers and Services, Professional Services, Health Care Technology, IT Services, and others.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.